Investors Are Urged To Participate In An Investigation Into Blueprint Medicines Corporation's Potential Securities Law Violations
Rhea-AI Summary
The Schall Law Firm is investigating potential securities law violations by Blueprint Medicines (NASDAQ: BPMC). The investigation centers on whether Blueprint issued false or misleading statements to investors. On August 17, 2022, Blueprint announced top-line results from Part 2 of its PIONEER clinical trial for AYVAKIT® (avapritinib). The company revealed that the absolute improvement in symptom score decreased from 19.7 in Part 1 to 15.6 in Part 2. This news caused Blueprint's stock to fall by 10% on the same day.
Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights. The firm specializes in securities class action lawsuits and shareholder rights litigation. It's important to note that the class in this case has not yet been certified, and affected shareholders are not currently represented by an attorney unless they take action.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BPMC declined 2.04%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Blueprint announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) on August 17, 2022. The Company disclosed that the absolute improvement in the symptom score fell from 19.7 in the first part of the trial to 15.6 in part 2. Based on this news, shares of Blueprint fell by
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
SOURCE: The Schall Law Firm
View the original press release on accesswire.com
FAQ
What is the Schall Law Firm investigating regarding Blueprint Medicines (BPMC)?
What caused Blueprint Medicines (BPMC) stock to drop 10% on August 17, 2022?
How can affected shareholders of Blueprint Medicines (BPMC) participate in the investigation?
Has a class been certified for the Blueprint Medicines (BPMC) investigation?
